For kidney transplant assessment
Covered by Medicare, Prospera is a transplant rejection assessment test that uses a simple blood draw to evaluate the risk of rejection of a transplanted kidney.
Through the use of advanced cell-free DNA technology, Prospera increases a provider’s ability to identify otherwise undetected rejection that might lead to kidney loss. Catching transplant rejection as soon as possible can help providers develop a treatment plan to best protect the donated kidney.
Setting a new standard through research
Best-in-class care depends on best-in-class assessment
Prospera is the most advanced cfDNA solution for assessing transplant rejection — reinforced by ongoing research efforts.